HUP0301862A3 - Lactam compound, pharmaceutical composition containing it, process for producing it, intermediates and use of it for producing pharmaceutical composition - Google Patents
Lactam compound, pharmaceutical composition containing it, process for producing it, intermediates and use of it for producing pharmaceutical compositionInfo
- Publication number
- HUP0301862A3 HUP0301862A3 HU0301862A HUP0301862A HUP0301862A3 HU P0301862 A3 HUP0301862 A3 HU P0301862A3 HU 0301862 A HU0301862 A HU 0301862A HU P0301862 A HUP0301862 A HU P0301862A HU P0301862 A3 HUP0301862 A3 HU P0301862A3
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical composition
- producing
- intermediates
- lactam compound
- composition containing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- -1 Lactam compound Chemical class 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Cephalosporin Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24965600P | 2000-11-17 | 2000-11-17 | |
| PCT/US2001/027795 WO2002040451A2 (en) | 2000-11-17 | 2001-11-02 | Lactam compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0301862A2 HUP0301862A2 (hu) | 2003-09-29 |
| HUP0301862A3 true HUP0301862A3 (en) | 2007-09-28 |
Family
ID=22944436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0301862A HUP0301862A3 (en) | 2000-11-17 | 2001-11-02 | Lactam compound, pharmaceutical composition containing it, process for producing it, intermediates and use of it for producing pharmaceutical composition |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20040248878A1 (OSRAM) |
| EP (1) | EP1353910B1 (OSRAM) |
| JP (1) | JP4116431B2 (OSRAM) |
| KR (1) | KR20030045194A (OSRAM) |
| CN (2) | CN101624372A (OSRAM) |
| AR (1) | AR031356A1 (OSRAM) |
| AT (1) | ATE362919T1 (OSRAM) |
| AU (2) | AU2002224321B2 (OSRAM) |
| BR (1) | BR0115424A (OSRAM) |
| CA (1) | CA2425497C (OSRAM) |
| CY (1) | CY1106682T1 (OSRAM) |
| CZ (1) | CZ20031340A3 (OSRAM) |
| DE (1) | DE60128587T2 (OSRAM) |
| DK (1) | DK1353910T3 (OSRAM) |
| DZ (1) | DZ3454A1 (OSRAM) |
| EA (1) | EA006919B1 (OSRAM) |
| EC (1) | ECSP034598A (OSRAM) |
| ES (1) | ES2286162T3 (OSRAM) |
| HR (1) | HRP20030385A2 (OSRAM) |
| HU (1) | HUP0301862A3 (OSRAM) |
| IL (1) | IL155275A0 (OSRAM) |
| MX (1) | MXPA03004250A (OSRAM) |
| MY (1) | MY141607A (OSRAM) |
| NO (1) | NO325217B1 (OSRAM) |
| PE (1) | PE20020798A1 (OSRAM) |
| PL (1) | PL211018B1 (OSRAM) |
| PT (1) | PT1353910E (OSRAM) |
| SK (1) | SK287794B6 (OSRAM) |
| SV (1) | SV2003000741A (OSRAM) |
| TW (1) | TWI235151B (OSRAM) |
| UA (1) | UA77165C2 (OSRAM) |
| WO (1) | WO2002040451A2 (OSRAM) |
| ZA (1) | ZA200303411B (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA74849C2 (en) * | 2000-11-17 | 2006-02-15 | Lilly Co Eli | Lactam |
| ES2333008T3 (es) | 2002-12-20 | 2010-02-16 | Glaxo Group Limited | Derivados de benzo(d)azepina para el tratamiento de trastornos neurologicos. |
| EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| BRPI0610532A2 (pt) | 2005-04-08 | 2010-06-29 | Daiichi Sankyo Co Ltd | derivado de piridilmetilsulfona |
| US8258302B2 (en) * | 2006-01-31 | 2012-09-04 | Api Corporation | Method for producing benzazepinone |
| TW200920362A (en) | 2007-09-11 | 2009-05-16 | Daiichi Sankyo Co Ltd | Alkylsulfone derivatives |
| FR2932800B1 (fr) * | 2008-06-20 | 2015-02-20 | Servier Lab | Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| KR101899014B1 (ko) | 2012-01-06 | 2018-09-17 | 삼성전자주식회사 | 비엘디씨 모터의 제어 장치 및 그 방법 |
| CN102690231B (zh) * | 2012-04-11 | 2014-07-09 | 南京友杰医药科技有限公司 | 治疗阿尔茨海默病潜在药物司马西特的合成方法 |
| US20160067306A1 (en) | 2013-04-19 | 2016-03-10 | National University Corporation Hokkaido University | Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these |
| CN116850181A (zh) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
| AU2016284162A1 (en) | 2015-06-22 | 2018-02-01 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders |
| AU2018220521A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| WO2019236757A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| IL296723A (en) | 2020-03-26 | 2022-11-01 | Seagen Inc | Methods of treating multiple myeloma |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158355A0 (en) * | 1996-12-23 | 2004-05-12 | Elan Pharm Inc | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS beta-AMYLOID PEPTIDE RELEASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| CA2324474A1 (en) * | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| EP1230220A1 (en) * | 1999-11-09 | 2002-08-14 | Eli Lilly And Company | Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis |
-
2001
- 2001-02-11 UA UA2003054406A patent/UA77165C2/uk unknown
- 2001-11-02 JP JP2002542779A patent/JP4116431B2/ja not_active Expired - Fee Related
- 2001-11-02 EA EA200300579A patent/EA006919B1/ru unknown
- 2001-11-02 PT PT01996530T patent/PT1353910E/pt unknown
- 2001-11-02 BR BR0115424-9A patent/BR0115424A/pt not_active Application Discontinuation
- 2001-11-02 DK DK01996530T patent/DK1353910T3/da active
- 2001-11-02 CA CA2425497A patent/CA2425497C/en not_active Expired - Fee Related
- 2001-11-02 DE DE60128587T patent/DE60128587T2/de not_active Expired - Lifetime
- 2001-11-02 AU AU2002224321A patent/AU2002224321B2/en not_active Ceased
- 2001-11-02 HU HU0301862A patent/HUP0301862A3/hu unknown
- 2001-11-02 CZ CZ20031340A patent/CZ20031340A3/cs unknown
- 2001-11-02 AT AT01996530T patent/ATE362919T1/de active
- 2001-11-02 DZ DZ013454A patent/DZ3454A1/fr active
- 2001-11-02 HR HR20030385A patent/HRP20030385A2/hr not_active Application Discontinuation
- 2001-11-02 WO PCT/US2001/027795 patent/WO2002040451A2/en not_active Ceased
- 2001-11-02 AU AU2432102A patent/AU2432102A/xx active Pending
- 2001-11-02 KR KR10-2003-7006660A patent/KR20030045194A/ko not_active Ceased
- 2001-11-02 CN CN200910203885A patent/CN101624372A/zh active Pending
- 2001-11-02 ES ES01996530T patent/ES2286162T3/es not_active Expired - Lifetime
- 2001-11-02 US US10/415,548 patent/US20040248878A1/en not_active Abandoned
- 2001-11-02 IL IL15527501A patent/IL155275A0/xx unknown
- 2001-11-02 SK SK543-2003A patent/SK287794B6/sk not_active IP Right Cessation
- 2001-11-02 MX MXPA03004250A patent/MXPA03004250A/es active IP Right Grant
- 2001-11-02 EP EP01996530A patent/EP1353910B1/en not_active Expired - Lifetime
- 2001-11-02 CN CNB018189962A patent/CN100516047C/zh not_active Expired - Fee Related
- 2001-11-02 PL PL360991A patent/PL211018B1/pl unknown
- 2001-11-15 TW TW090128351A patent/TWI235151B/zh not_active IP Right Cessation
- 2001-11-15 AR ARP010105339A patent/AR031356A1/es not_active Application Discontinuation
- 2001-11-15 MY MYPI20015251A patent/MY141607A/en unknown
- 2001-11-16 SV SV2001000741A patent/SV2003000741A/es unknown
- 2001-11-16 PE PE2001001143A patent/PE20020798A1/es not_active Application Discontinuation
-
2003
- 2003-05-02 ZA ZA200303411A patent/ZA200303411B/en unknown
- 2003-05-13 EC EC2003004598A patent/ECSP034598A/es unknown
- 2003-05-15 NO NO20032215A patent/NO325217B1/no unknown
-
2007
- 2007-06-28 CY CY20071100848T patent/CY1106682T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0301842A3 (en) | Lactam compound, pharmaceutical composition containing it and use of it for producing pharmaceutical composition | |
| HUP0302257A3 (en) | 4-hydrazino-5-hydroxy-5-pyrazol derivatives, pharmaceutical compositions containing them, process for producing them and their intermediates | |
| HUP0302519A3 (en) | Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them | |
| HUP0402063A3 (en) | Indole-2-carboxamides process for producing them, pharmaceutical compositions containing them and use thereof | |
| HUP0301802A3 (en) | Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it | |
| HUP0301459A3 (en) | Chemical compounds process for producing them and pharmaceutical compositions containing them | |
| HUP0303128A3 (en) | Novel succinate salt of o-desmethyl-venlafaxine, process for preparation thereof, its use and pharmaceutical composition containing it | |
| HUP0301862A3 (en) | Lactam compound, pharmaceutical composition containing it, process for producing it, intermediates and use of it for producing pharmaceutical composition | |
| PL343726A1 (en) | 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds | |
| HUP0300826A3 (en) | Polymorphs of an epothilone analog, process for their preparation and pharmaceutical compositions containing them | |
| HUP0402264A3 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof | |
| HUP0300057A3 (en) | Glucopyranosyloxy benzylbenzene derivatives, pharmaceutical compositions containing the same and intermediates for the preparation of the derivatives | |
| HUP0302358A3 (en) | Piperazinedione compounds and use of them for producing pharmaceutical compositions | |
| HUP0301463A3 (en) | Process for the preparation of substituted octanoyl amides and the intermediates | |
| HUP0103987A3 (en) | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates | |
| HUP0105108A3 (en) | Amide compounds, process for their preparation and pharmaceutical compositions containing them | |
| HUP0301811A3 (en) | Compounds having hypolipedemic and hypocholesteremic activities, process for their prreparation and pharmaceutical compositions containing them and their use, intermediates | |
| HUP0401747A3 (en) | Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds | |
| HUP0204563A3 (en) | Process for preparation of 3,3-diarylpropylamine derivatives and their intermediates and their use for preparation of pharmaceutical compositions | |
| HUP0400350A3 (en) | Novel cyano-substituted dihydropyrimidine compounds, process for producing them, their use and pharmaceutical compositions containing them | |
| HUP0100489A3 (en) | New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them | |
| HUP0302429A3 (en) | 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use | |
| HUP0202322A2 (en) | A substantially crystalline form of melagatran, process for obtaining it, pharmaceutical composition containing thereof and its use | |
| HUP0202379A3 (en) | New compounds, process for producing them and pharmaceutical compositions containing them | |
| HUP0105456A2 (en) | Aspartate derivative of amlodipine, process for producing it and pharmaceutical composition containing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |